Indinavir urolithiasis

Current Opinion in Urology

Volumn 10, Issue 6, 2000, Pages 557-561

  Wu, David Sweg Hsien ^a   Stoller, Marshall Leedy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM OXALATE; CD4 ANTIGEN; INDINAVIR; VIRUS RNA;

DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SOLUBILITY; HEMATURIA; HUMAN; LYMPHOCYTE COUNT; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; T LYMPHOCYTE; UROLITHIASIS;

HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; URINARY CALCULI;

EID: 0033695820     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200011000-00004     Document Type: Review

References (26)

1. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
2. HIV protease inhibitors
3. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. Clinical experience with saquinavir
5. New drugs for HIV infection
6. A double-blind randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine-naive patients
7. Preliminary evaluation of the long term safety and antiviral activity exerted by Crixivan (MK-639), an oral HIV protease inhibitor
8. Prophylaxis for occupational exposure to HIV
9. A new type of urinary calculus: Indinavir
10. Protease inhibitors and urolithiasis
11. Urolithiasis and the protease inhibitor indinavir
12. HIV protease inhibitors
13. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
14. Synthetic HIV protease inhibitor with antiviral activity arresting HIV-like particle maturation
15. Antiviral synergy between inhibitor of HIV proteinase and reverse transcriptase
16. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed
17. Indinavir nephropathy
18. Urinary stones in HIV-1 positive patients treated with indinavir
19. Crystalluria and urinary tract abnormalities associated with indinavir
20. Protese inhibitor-induced urolithiasis
21. Imaging characteristics of indinavir calculi
22. Urolithiasis associated with the protease inhibitor indinavir
23. Indinavir urolithiasis: An emerging cause of renal colic in patients with human immunodeficiency virus
24. Management of indinavir associated nephrolithiasis
25. Nephrolithiasis from indinavir, a new human immunodeficiency virus drug